Phase 3 Readout

DBVT: Phase 3 Topline: A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous I

Name: Phase 3 Topline: A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous I
Start: 2028-05-01
End: 2028-05-01

May 1, 2028 · dbv712. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: May 1, 2028
Company: DBV Technologies S.A. (DBVT)
Drug: dbv712

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous I

May 1, 2028

DBVT overview →

Company: DBV Technologies S.A. (DBVT)
Drug: dbv712
Indication: Allergy; Peanut Allergy